A Health-Related Quality of Life Measure for Patients Who Undergo Minimally Invasive Glaucoma Surgery.

Autor: Hays RD; Department of Medicine (RDH), University of California, Los Angeles, California, USA; The RAND Corporation (RDH), Santa Monica, California, USA. Electronic address: drhays@ucla.edu., Tarver ME; US Food and Drug Administration (MET and ME), Center for Devices and Radiologic Health, Silver Spring, Maryland, USA., Eydelman M; US Food and Drug Administration (MET and ME), Center for Devices and Radiologic Health, Silver Spring, Maryland, USA., Spaeth GL; Wills Eye Hospital, Sidney Kimmel School of Medicine (GLS), Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Parke DW 2nd; Verana Health (DWP), San Francisco, California, USA., Singh K; Stanford University School of Medicine (KS), Stanford, California, USA., Nguyen D, Saltzmann RM, Smith O, Shaw ML, Rosenberg L, Seibold L, Teymoorian S, Provencher LM, Bicket AK, Arora N, Junk AK, Chaya C, Salim S, Kuo D, Weiner A, Zhang Z, Rhee BFD, McMillan B, Choo C, Garris W, Noecker R, Fellman R, Caprioli J, Vold S, Pasquale L, Cui Q, Mbagwu M
Jazyk: angličtina
Zdroj: American journal of ophthalmology [Am J Ophthalmol] 2024 Oct; Vol. 266, pp. 313-320. Date of Electronic Publication: 2024 Jun 15.
DOI: 10.1016/j.ajo.2024.05.031
Abstrakt: Purpose: To develop a patient-reported outcome measure to assess the impact of glaucoma and treatment, including minimally invasive glaucoma surgery (MIGS).
Design: Observational study before and after concomitant cataract and Food and Drug Administration-approved implantable MIGS device surgery.
Setting: Survey administration was on a computer, iPad, or similar device.
Patient Population: 184 adults completed the baseline survey, 124 a survey 3 months after surgery, and 106 the 1-month test-retest reliability survey. The age range was 37 to 89 (average age = 72). Most were female (57%), non-Hispanic White (81%), and had a college degree (56%).
Main Outcome Measures: The Glaucoma Outcomes Survey (GOS) assesses functional limitations (27 items), vision-related symptoms (7 items), psychosocial issues (7 items), and satisfaction with microinvasive glaucoma surgery (1 item). These multiple-item scales were scored on a 0 to 100 range, with a higher score indicating worse health.
Results: Internal consistency reliability estimates ranged from 0.75 to 0.93, and 1-month test-retest intraclass correlations ranged from 0.83 to 0.92 for the GOS scales. Product-moment correlations among the scales ranged from 0.56 to 0.60. Improvement in visual acuity in the study eye from baseline to the 3-month follow-up was significantly related to improvements in GOS functional limitations (r = 0.18, P = .0485), vision-related symptoms (r = 0.19, P = .0386), and psychosocial concerns (r = 0.18, P = .0503). Responders to treatment ranged from 17% for vision-related symptoms to 48% for functional limitations.
Conclusions: This study supports using the GOS for ophthalmic procedures such as MIGS. Further evaluation of the GOS in different patient subgroups and clinical settings is needed.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: